In my view: Which thyroxine?

Thyroid

Volumn 15, Issue 2, 2005, Pages 124-126

  Toft, Anthony ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROTROPIN; THYROXINE;

BIOEQUIVALENCE; BONE DENSITY; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; THYROXINE BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; DRUG INDUSTRY; HYPERTHYROIDISM; REVIEW; STANDARD;

DRUG INDUSTRY; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; THYROXINE;

EID: 21744461000     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.124     Document Type: Short Survey

References (19)

1. Blakesly V, Awni W, Locke C, et al. 2004 Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 14:191-200.
2. Bell GM, Sawers JSA, Forfar JC, et al. 1983 The effects of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol 18:511-516.
3. Nystrom E, Lundberg P-A, Petersen K, et al. 1989 Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic L-thyroxine treatment. Clin Endocrinol 31:143-150.
4. Ross DS, Neer RM, Ridgway EC, et al. 1987 Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 82:1167-1170.
5. Surks MI, Chopra IJ, Mariash CN, et al. 1990 American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 263:1529-1532.
6. Surks MI, Ortiz E, Daniels GH, et al. 2004 Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 291:228-238.
7. Sawin CT, Geller A, Wolf PA, et al. 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 331:1249-1252.
8. Uzzan B, Campos J, Cucherat M, et al. 1996 Effects on bone mass of long-term treatment with thyroid hormone: a metaanalysis. J Clin Endocrinol Metab 81:4278-4289.
9. Cummings SR, Nevitt MC, Brown NWS, et al. 1995 Risk factors for hip fracture in white women. N Engl J Med 332:767-773.
10. Parle JV, Maisonneuve P, Sheppard MC, et al. 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result; a 10-year cohort study. Lancet 358:861-865.
11. Fatourechi V 2001 Adverse effects of subclinical hyperthyroidism. Lancet 358:856-857.
12. Toft AD, Beckett GJ 2003 Thyroid function tests and hypothyroidism. Br Med J 326:295-296.
13. Saravanan P, Chau WF, Roberts N, et al. 2002 Psychological well-being in patients on "adequate" doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol 57:577-585.
14. Carr D, McLeod DT, Parry G, et al. 1988 Fine adjustments of thyroxine replacement dosage: comparison of the thyrotrophin-releasing hormone test using a sensitive thyrotrophin assay with measurements of free thyroid hormones and clinical assessment. Clin Endocrinol 28:325-333.
15. Vanderpump MP, Ahlquist JA, Franklyn JA, et al. 1996 Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. Br Med J 313:539-544.
16. American Thyroid Association, the Endocrine Society, and American Association of Clinical Endocrinologists. 2004 Joint statement on the U.S. Food and Drug Administration decision regarding bioequivalence of levothyroxine sodium. Thyroid 14:486.
17. Thyroid Foundation of America. 2004 Advice to patients. Thyroid 14:487.
18. Surks MI, Ortiz E, Daniels GH, et al. 2004 Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 291:228-238.
19. Oppenheimer JH, Braverman LE, Toft AD, et al. 1995 Thyroid hormone treatment: when and what? J Clin Endocrinol Metab 80:2873-2883.